Physician profile
Melissa B Erickson
NPI 1730163601
$521,942.09
in general payments reported to CMS, 2019-2025
23 companies · $119K in 2025
The $119K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $27K · 2021: $64K · 2022: $102K · 2023: $86K · 2024: $92K · 2025: $119K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $122K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $102K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $19K · Food and Beverage: $11K · Honoraria: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $121,585.23 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $101,520.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,735.00 |
| Travel and Lodging | $18,763.30 |
| Food and Beverage | $11,302.61 |
| Honoraria | $692.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $134,606.53 | 2022-2025 | Miebo, Zenlens, Xiidra |
| Alcon Vision LLC | $71,531.64 | 2019-2025 | Dailies Total1, Total30, Tryptyr |
| Allergan, INC. | $54,184.24 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $52,587.12 | 2019-2025 | Acuvue |
| Abb Con-Cise Optical Group LLC | $47,108.95 | 2019-2025 | Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30,984.69 | 2019-2021 | |
| Dompe US, INC. | $30,099.01 | 2019-2025 | Oxervate |
| Glaukos Corporation | $24,940.31 | 2021-2025 | Ce-Marked Kxla System, Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Oyster Point Pharma, INC. | $14,836.06 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $14,239.97 | 2022-2025 | |
| Coopervision INC. | $13,188.25 | 2019-2025 | Clariti Contact Lens, Synergeyes Contact Lens, Paragon Crt |
| Sun Pharmaceutical Industries INC. | $11,392.08 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $6,071.60 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $5,302.00 | 2019-2023 | Tearcare System |
| Thea Pharma INC. | $4,158.54 | 2022-2024 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $2,700.00 | 2025 | Tryptyr |
| Nordic Pharma, INC. | $2,100.00 | 2025 | Lacrifill |
| Osmotica Pharmaceutical Corp. | $675.00 | 2020 | |
| Visioneering Technologies, INC. | $512.87 | 2019 | |
| Shire North American Group INC | $310.00 | 2019 | |
| Harrow Eye, LLC | $249.68 | 2025 | Vevye |
| Carl Zeiss Meditec, INC. | $139.40 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $24.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.